BioAtla, Inc. reported strong progress in its Q3 2025 earnings, achieving crucial FDA alignment for a phase three trial in oropharyngeal squamous cell carcinoma and setting the stage for a strategic partnership by year-end.

• Secured FDA agreement on the phase three OSV trial design for OPSCC, enabling potential accelerated and full approval.
• Presentation of promising interim data for the dual CAB EpCAM TCE (BA 3182) at ESMO enhances commercial and therapeutic confidence.
• Significant market opportunity for the OSFI program estimated at $800 million in peak sales for OPSCC, with broader HPV-positive solid tumors exceeding $7 billion globally.
• Development milestone achieved with Context Therapeutics underlines the CAB T cell engager platform's potential and provides non-dilutive capital.
• OSFI demonstrates compelling activity in heavily pretreated patients, marking a significant advancement in current treatment options.